Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
Coherus BioSciences today announced positive topline results for the first of 3 pharmacokinetic bioequivalence studies comparing CHS-1420, an adalimumab biosimilar candidate, and European-sourced reference Humira.
The California-based biosimilar developer said that the study (a randomized, single-blind, single-dose, parallel-group study in 216 healthy subjects) met its 3 primary endpoints: maximum serum concentration, area under the time-concentration curve from first to last time point measured, and area under the time-concentration curve from first time point extrapolated to infinity. The 90% confidence intervals of the geometric mean ratios for all PK endpoints fell within predefined bioequivalence boundaries of 80% to 125%.
News of Coherus’ results comes just days after the FDA approved another adalimumab biosimilar, Boehringer Ingelheim’s (BI) Cyltezo, for multiple indications. BI is also currently investigating interchangeability between its product and Humira.
However, while AbbVie faces mounting competition for its top-selling treatment, it is unlikely that the drug maker will see immediate erosion of its sales in the US marketplace; earlier this month, AbbVie filed suit against BI, claiming that the biosimilar developer will infringe on 74 of its patents covering Humira. With only 8 of those patents currently being litigated, the case could take a substantial period of time and investment of resources to resolve.
Likewise, the first US-approved adalimumab biosimilar, Amgen’s Amjevita, is still awaiting its launch after receiving the FDA’s approval in September of 2016. Litigation in AbbVie v Amgen is ongoing, with the case recently reassigned to a visiting judge in the Eastern District of Pennsylvania.
AbbVie faces a harder fight to protect its Humira sales in the international marketplace, however. In Australia, a federal court recently ruled that AbbVie cannot file for an extension of 3 of its patents on Humira because they protect methods of use rather than the drug itself.
Meanwhile, Samsung Bioepis’ own adalimumab biosimilar, Imraldi, was approved in the European Union last week after having received a previous positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use in June of 2017.
Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick
April 22nd 2025Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
President Trump Signs Executive Order to Bring Down Drug Prices
April 16th 2025To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar development, more transparency, and tougher rules on pharmacy benefit managers—aiming to save billions and make meds more affordable for everyone.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Experts Pressure Congress to Remove Roadblocks for Biosimilars
April 12th 2025Lawmakers and expert witnesses emphasized the potential of biosimilars to lower health care costs by overcoming barriers like pharmacy benefit manager practices, limited awareness, and regulatory delays to improve access and competition in chronic disease management during a recent congressional hearing.